Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis' treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns ​about the prospects of similar therapie...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。